Logo Logo
Help
Contact
Switch Language to German
Sebio, A.; Matsusaka, S.; Zhang, W.; Yang, D.; Ning, Y.; Stremitzer, S.; Stintzing, S.; Sunakawa, Y.; Yamauchi, S.; Fujimoto, Y.; Ueno, M.; Lenz, H-J (2016): Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer. In: Pharmacogenomics Journal, Vol. 16, No. 4: pp. 312-319
Full text not available from 'Open Access LMU'.

Abstract

The Hippo pathway regulates tissue growth and cell fate. In colon cancer, Hippo pathway deregulation promotes cellular quiescence and resistance to 5-Fluorouracil (5-Fu). In this study, 14 polymorphisms in 8 genes involved in the Hippo pathway (MST1, MST2, LATS1, LATS2, YAP, TAZ, FAT4 and RASSF1A) were evaluated as recurrence predictors in 194 patients with stages II/III colon cancer treated with 5-Fu-based adjuvant chemotherapy. Patients with a RASSF1A rs2236947 AA genotype had higher 3-year recurrence rate than patients with CA/CC genotypes (56 vs 33%, hazard ratio (HR): 1.87;P = 0.017). Patients with TAZ rs3811715 CT or TT genotypes had lower 3-year recurrence rate than patients with a CC genotype (28 vs 40%;HR: 0.66;P = 0.07). In left-sided tumors, this association was stronger (HR: 0.29;P = 0.011) and a similar trend was found in an independent Japanese cohort. These promising results reveal polymorphisms in the Hippo pathway as biomarkers for stages II and III colon cancer.